Insulin

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

Retrieved on: 
Tuesday, March 5, 2024

To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.

Key Points: 
  • To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.
  • View the full release here: https://www.businesswire.com/news/home/20240305266724/en/
    Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes.
  • The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes.
  • This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Retrieved on: 
Tuesday, March 5, 2024

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
  • There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology.
  • Today, Dexcom G7 is available for them with a prescription.
  • To learn more about Stelo and do a benefits check to see if you’re eligible to get started now with Dexcom G7, visit https://www.dexcom.com/en-us/stelo .

Drew Barrymore Announces She’s the New Brand Ambassador for Dr. Kellyann's Breakthrough Perimenopause and Menopause Formula

Retrieved on: 
Thursday, February 29, 2024

Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.

Key Points: 
  • Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.
  • The influential voice of Drew Barrymore is helping more women than ever to feel comfortable and empowered to take control of their hormones, in a safe and natural way during perimenopause and menopause.
  • Dr. Kellyann and Drew Barrymore teamed up after Drew tried Dr. Kellyann &ME Peri + Menopause for 3 months and had incredible results.
  • To learn more about Dr. Kellyann &ME Peri + Menopause visit drkellyann.com or join the menopause conversation by following @drkellyannpetrucci across social.

Global Insulin Pen Market Report 2024: A $14.1 Billion Forecasted Market by 2028, Registering Compound Annual Growth Rate of 6% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

The global insulin pen market was valued at $9.9 billion in 2022.

Key Points: 
  • The global insulin pen market was valued at $9.9 billion in 2022.
  • The market is expected to grow at a compound annual growth rate (CAGR) of 6.1%, reaching $14.1 billion by the end of 2028.
  • In 2022, the reusable insulin pen segment held the highest market share at about 51.5%, followed by disposable pens at 48.5%.
  • This report thoroughly examines the worldwide market size of global insulin pen delivery technology, enhancing its appeal to stakeholders and readers alike.

Diabetes Research Study in Santa Clarita Evaluating a New Approach To Helping Patients

Retrieved on: 
Monday, February 26, 2024

A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • “For many people living with diabetes, controlling blood glucose levels is a difficult journey,” said Dr. Sina Tebi, Principal Investigator at Care Access - Santa Clarita.
  • The local setting provides residents of Santa Clarita and surrounding communities the option to participate in clinical studies close to home.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Diabetes Research Study Evaluating a New Approach To Helping Patients Now Offered in Warwick

Retrieved on: 
Monday, February 26, 2024

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • (Photo: Business Wire)
    The combination of diabetes and obesity significantly increases one’s risk of heart attacks, stroke, liver disease, kidney disease, and other serious health problems.
  • Care Access is a global clinical research company helping to accelerate the future of medicine.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.